✦ LIBER ✦

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

✍ Scribed by Cizkova, M; Dujaric, M-E; Lehmann-Che, J; Scott, V; Tembo, O; Asselain, B; Pierga, J-Y; Marty, M; de Cremoux, P; Spyratos, F; Bieche, I

Book ID: 120248036
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 247 KB
Volume: 108
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.2013.164

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

244 PI3KCA Mutations in HER2-Positive Br

244 PI3KCA Mutations in HER2-Positive Breast Carcinomas Treated with Trastuzumab

✍ A. Ferro; M. Barbareschi; L.v. Cuorvo; S. Girlando; E. Leonardi; R. Triolo; A. C 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Prognostic value of phosphorylated HER2

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab

✍ Kurebayashi, Junichi; Kanomata, Naoki; Yamashita, Tetsumasa; Shimo, Toshiro; Miz 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 412 KB

Management and Outcome of HER2-Positive

Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era

✍ Carlo Palmieri; Deep Shah; Jonathan Krell; Ondrej Gojis; Katy Hogben; Pippa Ridd 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 432 KB

Trastuzumab-based neoadjuvant therapy in

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

✍ Helena R. Chang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 2 views

Immunohistochemical expression of HER1,

Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

✍ Kan Yonemori; Koji Tsuta; Chikako Shimizu; Yutaka Hatanaka; Akihiro Hirakawa; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

Quantitative HER2 protein levels predict

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

✍ Allan Lipton; Wolfgang J. Köstler; Kim Leitzel; Suhail M. Ali; Jeff Sperinde; Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB 👁 2 views

## Abstract ## BACKGROUND: Only a portion of breast cancer patients currently selected for trastuzumab therapy respond. ## METHODS: Using a novel assay (HERmark) to quantify total human epidermal growth factor receptor 2 (HER2) expression, the authors examined outcomes in 102 trastuzumab‐treated